Af­ter two years of ne­go­ti­a­tions, FDA gets its user fee pro­grams au­tho­rized through 2022

Pres­i­dent Don­ald Trump signed the FDA Reau­tho­riza­tion Act of 2017 in­to law late Fri­day, qui­et­ly end­ing a two-year long process that un­til sev­er­al weeks ago threat­ened to dis­rupt agency op­er­a­tions.

Al­though the leg­is­la­tion was passed by both hous­es of Con­gress with over­whelm­ing bi­par­ti­san sup­port — Sen­a­tor Bernie Sanders was the on­ly reg­is­tered no vote — it faced a num­ber of threats, in­clud­ing the White House’s clear de­sire to fund the FDA en­tire­ly with user fees from the com­pa­nies the agency reg­u­lates and a sen­a­tor’s long stand­ing cru­sade to un­der­cut the agency with a sweep­ing new “right-to-try” di­rec­tive.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.